Lorenz C Hofbauer

List of Articles by Year in descending order

Source: //exaly.com/author-pdf/6554808/publications.pdf

Version: 2025-02-01

364 peer-reviewed articles	22,541 peer-reviewed citations	16129 64 peer-reviewed h-index	547470 3.72 score
401 documents	26641 doc citations	15382 70 h-index	44776 citing authors

#	Article	IF	Citations
1	Effect of Vitamin D3, Omega-3 Fatty Acids, and Exercise on Serum Sclerostin Levels and Bone Turnover Markers. Journal of Clinical Endocrinology and Metabolism, 2025, 110, e3101-e3108.	3.1	7
2	Oncogenic FLT3 internal tandem duplications (ITD) and CD45/PTPRC control osteoclast functions and bone microarchitecture. JBMR Plus, 2025, 9, .	1.5	2
3	Bone phenotype in male and female mice after knockdown of transferrin receptor 1 in osterix-expressing cells. JBMR Plus, 2025, 9, .	1.5	3
4	Switch From rhPTH1-84 to TransCon PTH With Individual Dose Adjustment in Adult Hypoparathyroidism—4-Week Results. Journal of the Endocrine Society, 2025, 9, .	0.2	4
5	Comparison of the effects of high dietary iron levels on bone microarchitecture responses in the mouse strains 129/Sv and C57BL/6J. Scientific Reports, 2024, 14, .	2.7	5
6	High serum levels of leucine-rich α-2 glycoprotein 1 (LRG-1) are associated with poor survival in patients with early breast cancer. Archives of Gynecology and Obstetrics, 2024, 309, 2789-2798.	1.4	8
7	Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase. Biochemical and Biophysical Research Communications, 2024, 710, 149841.	1.5	15
8	Denosumab—Protection for Bone and Beyond?. Journal of Clinical Endocrinology and Metabolism, 2024, 109, e2159-e2160.	3.1	3
9	Effects of dietary iron deficiency or overload on bone: Dietary details matter. Bone, 2024, 184, 117092.	2.3	2
10	MiR-144-5p and miR-21-5p do not drive bone disease in a mouse model of type 1 diabetes mellitus. JBMR Plus, 2024, 8, .	1.5	2
11	Hyperthyroidism-driven bone loss depends on BMP receptor Bmpr1a expression in osteoblasts. Communications Biology, 2024, 7, .	3.1	7
12	Differential microRNA expression patterns between TallyHo/JngJ mice and non-diabetic Swiss Webster Random/Jackson mice. JBMR Plus, 2024, 9, .	1.5	1
13	Bone phenotyping of murine hemochromatosis models with deficiencies of Hjv, Alk2, or Alk3: The influence of sex and the bone compartment. FASEB Journal, 2024, 38, .	2.3	3
14	Building Bone while Making Milk. New England Journal of Medicine, 2024, 391, 2052-2054.	26.4	2
15	Exploratory miRNA profiling from serum and bone tissue of mice with T1D-induced bone loss. Frontiers in Endocrinology, 2024, 15, .	2.8	0
16	Reduced Bone Mass and Increased Osteocyte Tartrate-Resistant Acid Phosphatase (TRAP) Activity, But Not Low Mineralized Matrix Around Osteocyte Lacunae, Are Restored After Recovery From Exogenous Hyperthyroidism in Male Mice. Journal of Bone and Mineral Research, 2023, 38, 131-143.	3.2	9
17	Rational engineering of glycosaminoglycan-based Dickkopf-1 scavengers to improve bone regeneration. Biomaterials, 2023, 297, 122105.	9.5	6
18	Transferrin receptor 2 deficiency promotes macrophage polarization and inflammatory arthritis. Redox Biology, 2023, 60, 102616.	9.0	23

#	Article	IF	Citations
19	Activation of distinct inflammatory pathways in subgroups of LR-MDS. Leukemia, 2023, 37, 1709-1718.	3.7	29
20	Deletion of transferrin receptor 2 (Tfr2) amplifies inflammation and bone loss in experimental inflammatory bowel disease in mice. Osteologie, 2023, 32, S2-S2.	0.1	0
21	Novel Insights into Osteoclast Energy Metabolism. Current Osteoporosis Reports, 2023, 21, 660-669.	3.9	54
22	Reduced Bone Regeneration in Rats With Type 2 Diabetes Mellitus as a Result of Impaired Stromal Cell and Osteoblast Function—A Computer Modeling Study. JBMR Plus, 2023, 7, .	1.5	5
23	Evaluation of circulating Dickkopf-1 as a prognostic biomarker in ovarian cancer patients. Clinical Chemistry and Laboratory Medicine, 2022, 60, 109-117.	2.0	7
24	The Thyroid Hormone Transporter MCT10 Is a Novel Regulator of Trabecular Bone Mass and Bone Turnover in Male Mice. Endocrinology, 2022, 163, .	1.8	10
25	Skeletal health in patients following allogeneic hematopoietic cell transplantation. Bone, 2022, 158, 115684.	2.3	5
26	Bone fragility in diabetes: novel concepts and clinical implications. Lancet Diabetes and Endocrinology,the, 2022, 10, 207-220.	12.4	422
27	Exosomal miRNAs from Prostate Cancer Impair Osteoblast Function in Mice. International Journal of Molecular Sciences, 2022, 23, 1285.	3.2	31
28	Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial. American Journal of Clinical Nutrition, 2022, 115, 1311-1321.	3.2	33
29	Bad to the Bone: The Effects of Therapeutic Glucocorticoids on Osteoblasts and Osteocytes. Frontiers in Endocrinology, 2022, 13, .	2.8	82
30	Bone cell-specific deletion of thyroid hormone transporter Mct8 distinctly regulates bone volume in young versus adult male mice. Bone, 2022, 159, 116375.	2.3	8
31	The Impact of COVID-19 in Bone Metabolism: Basic and Clinical Aspects. Hormone and Metabolic Research, 2022, 54, 540-548.	1.0	8
32	The mevalonate pathway in breast cancer biology. Cancer Letters, 2022, 542, 215761.	6.5	23
33	Thyroid hormone receptor knockout differentially affects osteoblast and osteoclast differentiation and activity in vitro. Bone Reports, 2022, 16, 101380.	1.2	0
34	Loss of Adipogenic Dickkopf-1 prevents the expansion of bone marrow adipose tissue and tends to ameliorate bone loss under High-Fat Diet in Male Mice. Bone Reports, 2022, 16, 101221.	1.2	0
35	Porcupine inhibition normalizes Wnt activity, osteoblast excess, and impaired erythropoiesis in myelodysplastic mice. Bone Reports, 2022, 16, 101382.	1.2	0
36	MicroRNA and Diabetic Bone Disease. Current Osteoporosis Reports, 2022, 20, 194-201.	3.9	17

#	Article	IF	Citations
37	Effect of Anti-Osteoporotic Treatments on Circulating and Bone MicroRNA Patterns in Osteopenic ZDF Rats. International Journal of Molecular Sciences, 2022, 23, 6534.	3.2	7
38	Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer. Oncogene, 2022, 41, 3747-3760.	5.2	12
39	Iron effects versus metabolic alterations in hereditary hemochromatosis driven bone loss. Trends in Endocrinology and Metabolism, 2022, 33, 652-663.	8.0	32
40	Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism. Journal of Bone and Mineral Research, 2022, 37, 2315-2329.	3.2	200
41	Dimorphic Mechanisms of Fragility in Diabetes Mellitus: the Role of Reduced Collagen Fibril Deformation. Journal of Bone and Mineral Research, 2022, 37, 2259-2276.	3.2	20
42	Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice. Leukemia, 2022, 36, 2715-2718.	3.7	5
43	Romosozumab efficacy and safety in European patients enrolled in the FRAME trial. Osteoporosis International, 2022, 33, 2527-2536.	2.7	17
44	Low Bone Turnover Due to Hypothyroidism or Anti-Resorptive Treatment Does Not Affect Whole-Body Glucose Homeostasis in Male Mice. Journal of Personalized Medicine, 2022, 12, 1462.	1.9	4
45	Circulating Dickkopf1 Parallels Metabolic Adaptations and Predicts Disease Trajectories in Patients With COVID-19. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 3370-3377.	3.1	4
46	Compartment-specific mutational landscape of clonal hematopoiesis. Leukemia, 2022, 36, 2647-2655.	3.7	17
47	Clinical impact of soluble Neuropilin-1 in ovarian cancer patients and its association with its circulating ligands of the HGF/c-MET axis. Frontiers in Oncology, 2022, 12, .	1.7	7
48	Irisin and Bone in Sickness and in Health: A Narrative Review of the Literature. Journal of Clinical Medicine, 2022, 11, 6863.	1.8	16
49	Impact of Sulfated Hyaluronan on Bone Metabolism in Diabetic Charcot Neuroarthropathy and Degenerative Arthritis. International Journal of Molecular Sciences, 2022, 23, 15146.	3.2	5
50	Interactions of Anemia, FGF-23, and Bone in Healthy Adults—Results From the Study of Health in Pomerania (SHIP). Journal of Clinical Endocrinology and Metabolism, 2021, 106, e288-e299.	3.1	18
51	Emerging Players in Prostate Cancer–Bone Niche Communication. Trends in Cancer, 2021, 7, 112-121.	8.1	77
52	Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 264-281.	3.1	301
53	Role of osteogenic Dickkopf-1 in bone remodeling and bone healing in mice with type I diabetes mellitus. Scientific Reports, 2021, 11, .	2.7	22
54	Testosteronmangel im Alter – was ist zu tun?. Deutsche Medizinische Wochenschrift, 2021, 146, 141-145.	0.1	1

#	Article	IF	Citations
55	Mice lacking DKK1 in T cells exhibit high bone mass and are protected from estrogen-deficiency-induced bone loss. IScience, 2021, 24, 102224.	2.4	31
56	High stroma-derived WNT5A is an indicator for low-risk prostate cancer. FEBS Open Bio, 2021, 11, 1186-1194.	1.5	2
57	Extracellular vesicles from metastatic prostate cancer modulate osteoblastic functions. Bone Reports, 2021, 14, 100790.	1.2	0
58	Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2233-2238.	1.8	28
59	Novel approaches to target the microenvironment of bone metastasis. Nature Reviews Clinical Oncology, 2021, 18, 488-505.	54.3	191
60	From Pharmacology to Physiology: Endocrine Functions of μ-Opioid Receptor Networks. Trends in Endocrinology and Metabolism, 2021, 32, 306-319.	8.0	19
61	Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases. Bone Research, 2021, 9, .	10.7	31
62	Late-onset hypogonadism: Clinical evidence, biological aspects and evolutionary considerations. Ageing Research Reviews, 2021, 67, 101301.	9.0	26
63	Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells. Leukemia, 2021, 35, 2936-2947.	3.7	30
64	Erwiderung auf den Leserbrief zum Beitrag: „Testosteronmangel im Alter – was ist zu tun“. Deutsche Medizinische Wochenschrift, 2021, 146, 1017-1017.	0.1	1
65	Skeletal endocrinology: where evolutionary advantage meets disease. Bone Research, 2021, 9, .	10.7	13
66	The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone. International Journal of Molecular Sciences, 2021, 22, 5078.	3.2	42
67	Osteoporose bei Diabetes mellitus. Diabetes Aktuell, 2021, 19, 178-183.	0.0	0
68	Individualized Bone-Protective Management in Long-Term Cancer Survivors With Bone Metastases. Journal of Bone and Mineral Research, 2021, 36, 1906-1913.	3.2	12
69	Rodent Models of Spondyloarthritis Have Decreased White and Bone Marrow Adipose Tissue Depots. Frontiers in Immunology, 2021, 12, .	3.3	5
70	New insights into the role of glycosaminoglycans in the endosteal bone microenvironment. Biological Chemistry, 2021, 402, 1415-1425.	1.2	22
71	Shaping the bone through iron and iron-related proteins. Seminars in Hematology, 2021, 58, 188-200.	2.3	39
72	Systemic PPARγ Antagonism Reduces Metastatic Tumor Progression in Adipocyte-Rich Bone in Excess Weight Male Rodents. Journal of Bone and Mineral Research, 2021, 36, 2440-2452.	3.2	12

#	Article	IF	Citations
73	Epo/EpoR signaling in osteoprogenitor cells is essential for bone homeostasis and Epo-induced bone loss. Bone Research, 2021, 9, .	10.7	34
74	Knochenmetastasen: Stellenwert von Biomarkern bei der Frühdiagnose. , 2021, , .		0
75	Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcinoma of the prostate. International Journal of Cancer, 2020, 146, 2619-2627.	2.8	26
76	Lack of the Thyroid Hormone Transporter Mct8 in Osteoblast and Osteoclast Progenitors Increases Trabecular Bone in Male Mice. Thyroid, 2020, 30, 329-342.	3.0	17
77	Challenges in Preventing Bone Loss Induced by Aromatase Inhibitors. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3122-3133.	3.1	20
78	Is a treat-to-target strategy in osteoporosis applicable in clinical practice? Consensus among a panel of European experts. Osteoporosis International, 2020, 31, 2303-2311.	2.7	26
79	Cholesterol and beyond - The role of the mevalonate pathway in cancer biology. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1873, 188351.	5.8	144
80	Effects of androgen excess and glucocorticoid exposure on bone health in adult patients with 21-hydroxylase deficiency. Journal of Steroid Biochemistry and Molecular Biology, 2020, 204, 105734.	1.8	34
81	The Bone Morphogenetic Protein Pathway: The Osteoclastic Perspective. Frontiers in Cell and Developmental Biology, 2020, 8, .	2.8	43
82	Aberrant Bone Homeostasis in AML Is Associated with Activated Oncogenic FLT3-Dependent Cytokine Networks. Cells, 2020, 9, 2443.	3.3	5
83	Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults. JAMA - Journal of the American Medical Association, 2020, 324, 1855.	14.4	347
84	Disruption of the hepcidin/ferroportin regulatory circuitry causes low axial bone mass in mice. Bone, 2020, 137, 115400.	2.3	24
85	Disruption of BMP Signaling Prevents Hyperthyroidism-Induced Bone Loss in Male Mice. Journal of Bone and Mineral Research, 2020, 35, 2058-2069.	3.2	26
86	Serum Profile of microRNAs Linked to Bone Metabolism During Sequential Treatment for Postmenopausal Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2885-e2894.	3.1	19
87	Diagnostik und Therapie der Osteoporose bei geriatrischen Patienten. Deutsche Medizinische Wochenschrift, 2020, 145, 728-732.	0.1	5
88	Denosumab in postmenopausal women with osteoporosis and diabetes: Subgroup analysis of FREEDOM and FREEDOM extension. Bone, 2020, 134, 115268.	2.3	62
89	Thyroid Hormone Actions and Bone Remodeling – The Role of the Wnt Signaling Pathway. Experimental and Clinical Endocrinology and Diabetes, 2020, 128, 450-454.	0.9	28
90	Evolving functions of Dickkopf-1 in cancer and immunity. Cancer Letters, 2020, 482, 1-7.	6.5	34

#	Article	IF	Citations
91	Contributions of Dickkopf-1 to Obesity-Induced Bone Loss and Marrow Adiposity. JBMR Plus, 2020, 4, .	1.5	16
92	Dorsomorphin: A novel inhibitor of Dickkopf-1 in breast cancer. Biochemical and Biophysical Research Communications, 2020, 524, 360-365.	1.5	10
93	Increased FGF-23 levels are linked to ineffective erythropoiesis and impaired bone mineralization in myelodysplastic syndromes. JCI Insight, 2020, 5, .	3.7	28
94	Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes. Annals of Hematology, 2019, 98, 2063-2072.	1.0	11
95	Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells. Cell Death and Disease, 2019, 10, .	6.6	111
96	The Role of Dickkopf-1 in Thyroid Hormone–Induced Changes of Bone Remodeling in Male Mice. Endocrinology, 2019, 160, 664-674.	1.8	17
97	Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation. Oncogene, 2019, 38, 4773-4787.	5.2	13
98	Osteogenic Dkk1 Mediates Glucocorticoid-Induced but Not Arthritis-Induced Bone Loss. Journal of Bone and Mineral Research, 2019, 34, 1314-1323.	3.2	36
99	Increased pore size of scaffolds improves coating efficiency with sulfated hyaluronan and mineralization capacity of osteoblasts. Biomaterials Research, 2019, 23, .	5.8	50
100	Loss of Dkk-1 in Osteocytes Mitigates Alveolar Bone Loss in Mice With Periodontitis. Frontiers in Immunology, 2019, 10, .	3.3	31
101	Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer. Clinical Cancer Research, 2019, 25, 1369-1378.	4.5	37
102	Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signalling. Nature Metabolism, 2019, 1, 111-124.	14.3	82
103	Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. Bone, 2019, 120, 44-49.	2.3	27
104	Immunoadsorption Followed by Rituximab as a Definitive Treatment for Insulin Autoimmune Syndrome (Hirata Syndrome): A Case Report. Diabetes Care, 2018, 41, e23-e24.	5.6	17
105	Bone health during endocrine therapy for cancer. Lancet Diabetes and Endocrinology,the, 2018, 6, 901-910.	12.4	137
106	Thy-1 Deficiency Augments Bone Loss in Obesity by Affecting Bone Formation and Resorption. Frontiers in Cell and Developmental Biology, 2018, 6, .	2.8	15
107	Differential effects of high-fat diet and exercise training on bone and energy metabolism. Bone, 2018, 116, 120-134.	2.3	49
108	Postnatal Skeletal Deletion of Dickkopf-1 Increases Bone Formation and Bone Volume in Male and Female Mice, Despite Increased Sclerostin Expression. Journal of Bone and Mineral Research, 2018, 33, 1698-1707.	3.2	44

#	Article	IF	Citations
109	Selective inhibition of receptor activator of NF-κB ligand (RANKL) in hematopoietic cells improves outcome after experimental myocardial infarction. Journal of Molecular Medicine, 2018, 96, 559-573.	2.8	10
110	Associations of myeloid hematological diseases of the elderly with osteoporosis: A longitudinal analysis of routine health care data. Leukemia Research, 2018, 69, 81-86.	0.7	15
111	Thy-1 (CD90) promotes bone formation and protects against obesity. Science Translational Medicine, 2018, 10, .	8.7	98
112	Glucocorticoids suppress Wnt16 expression in osteoblasts in vitro and in vivo. Scientific Reports, 2018, 8, .	2.7	47
113	Myelodysplastic syndromes and bone loss in mice and men. Leukemia, 2017, 31, 1003-1007.	3.7	31
114	Neue osteoanabole Therapien zur Behandlung der Osteoporose. Deutsche Medizinische Wochenschrift, 2017, 142, 475-478.	0.1	0
115	Sclerostin Blockade and Zoledronic Acid Improve Bone Mass and Strength in Male Mice With Exogenous Hyperthyroidism. Endocrinology, 2017, 158, 3765-3777.	1.8	23
116	Prediction of Fractures and Major Cardiovascular Events in Men Using Serum Osteoprotegerin Levels: The Prospective STRAMBO Study. Journal of Bone and Mineral Research, 2017, 32, 2288-2296.	3.2	10
117	Immune Suppressive and Bone Inhibitory Effects of Prednisolone in Growing and Regenerating Zebrafish Tissues. Journal of Bone and Mineral Research, 2017, 32, 2476-2488.	3.2	65
118	Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells. Scientific Reports, 2017, 7, .	2.7	239
119	Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes and Endocrinology,the, 2017, 5, 898-907.	12.4	957
120	Site-Specific Variations in Bone Mineral Density under Systemic Conditions Inducing Osteoporosis in Minipigs. Frontiers in Physiology, 2017, 8, .	2.2	8
121	Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer. Breast Cancer Research, 2017, 19, .	3.4	27
122	Osteoonkologie: Von der Biologie zu neuen Therapien. , 2017, , .		0
123	The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease. PLoS ONE, 2016, 11, e0155087.	1.5	25
124	Microdialysis Sampling from Wound Fluids Enables Quantitative Assessment of Cytokines, Proteins, and Metabolites Reveals Bone Defect-Specific Molecular Profiles. PLoS ONE, 2016, 11, e0159580.	1.5	22
125	Increased EPO Levels Are Associated With Bone Loss in Mice Lacking PHD2 in EPO-Producing Cells. Journal of Bone and Mineral Research, 2016, 31, 1877-1887.	3.2	65
126	Functional Interference in the Bone Marrow Microenvironment by Disseminated Breast Cancer Cells. Stem Cells, 2016, 34, 2224-2235.	2.7	16

#	Article	IF	Citations
127	Milk Fat Globule-Epidermal Growth Factor 8 (MFG-E8) Is a Novel Anti-inflammatory Factor in Rheumatoid Arthritis in Mice and Humans. Journal of Bone and Mineral Research, 2016, 31, 596-605.	3.2	58
128	Diagnostik in der Osteologie. Der Internist, 2016, 57, 631-637.	0.4	1
129	Resection of Pheochromocytoma in a Patient Requiring Coronary Artery Bypass Grafting: First Things First. AACE Clinical Case Reports, 2016, 2, e25-e29.	0.4	2
130	Sulfated hyaluronan improves bone regeneration of diabetic rats by binding sclerostin and enhancing osteoblast function. Biomaterials, 2016, 96, 11-23.	9.5	67
131	GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporosis International, 2016, 27, 2967-2978.	2.7	48
132	Effects of insulin therapy on porosity, non-enzymatic glycation and mechanical competence in the bone of rats with type 2 diabetes mellitus. Bone, 2016, 91, 186-193.	2.3	9
133	Romosozumab Treatment in Postmenopausal Women with Osteoporosis. New England Journal of Medicine, 2016, 375, 1532-1543.	26.4	1,695
134	Postmenopausal osteoporosis. Nature Reviews Disease Primers, 2016, 2, .	37.8	764
135	Knochenmetastasen. Der Internist, 2016, 57, 666-674.	0.4	0
136	Effects of parathyroid hormone on cortical porosity, non-enzymatic glycation and bone tissue mechanics in rats with type 2 diabetes mellitus. Bone, 2016, 82, 116-121.	2.3	16
137	p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells. Cell Death and Disease, 2016, 7, e2119-e2119.	6.6	50
138	Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells. Cancer Letters, 2016, 375, 162-171.	6.5	50
139	Bone defect regeneration and cortical bone parameters of type 2 diabetic rats are improved by insulin therapy. Bone, 2016, 82, 108-115.	2.3	60
140	Role of milk fat globule-epidermal growth factor 8 in osteoimmunology. BoneKEy Reports, 2016, 5, .	2.2	6
141	WNT5A Has Anti-Prostate Cancer Effects In Vitro and Reduces Tumor Growth in the Skeleton In Vivo. Journal of Bone and Mineral Research, 2015, 30, 471-480.	3.2	47
142	Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies. International Journal of Endocrinology, 2015, 2015, 1-9.	1.1	29
143	Cancer-targeted therapies and radiopharmaceuticals. BoneKEy Reports, 2015, 4, .	2.2	2
144	Loss of bone strength in HLA-B27 transgenic rats is characterized by a high bone turnover and is mainly osteoclast-driven. Bone, 2015, 75, 183-191.	2.3	10

#	Article	IF	Citations
145	Structural and functional insights into sclerostin-glycosaminoglycan interactions in bone. Biomaterials, 2015, 67, 335-345.	9.5	47
146	Serum fetuin-A levels and abdominal aortic calcification in healthy men — The STRAMBO study. Bone, 2015, 79, 196-202.	2.3	17
147	Loss of milk fat globule-epidermal growth factor 8 (MFG-E8) in mice leads to low bone mass and accelerates ovariectomy-associated bone loss by increasing osteoclastogenesis. Bone, 2015, 76, 107-114.	2.3	27
148	Hyperthyroidism and Hypothyroidism in Male Mice and Their Effects on Bone Mass, Bone Turnover, and the Wnt Inhibitors Sclerostin and Dickkopf-1. Endocrinology, 2015, 156, 3517-3527.	1.8	61
149	Effects of adolescence-onset hypogonadism on metabolism, bone mineral density and quality of life in adulthood. Journal of Pediatric Endocrinology and Metabolism, 2015, 28, .	0.5	7
150	P38 regulates the Wnt inhibitor Dickkopf-1 in breast cancer. Biochemical and Biophysical Research Communications, 2015, 466, 728-732.	1.5	13
151	Bioinspired Collagen/Glycosaminoglycan-Based Cellular Microenvironments for Tuning Osteoclastogenesis. ACS Applied Materials & Interfaces, 2015, 7, 23787-23797.	5.5	45
152	Associations between ambient air pollution and bone turnover markers in 10-year old children: Results from the GINIplus and LISAplus studies. International Journal of Hygiene and Environmental Health, 2015, 218, 58-65.	3.0	28
153	Breast carcinoma cells modulate the chemoattractive activity of human bone marrow-derived mesenchymal stromal cells by interfering with CXCL12. International Journal of Cancer, 2015, 136, 44-54.	2.8	36
154	Associations between serum 25-hydroxyvitamin D and bone turnover markers in a population based sample of German children. Scientific Reports, 2015, 5, .	2.7	43
155	Thyrotropin serum levels are differentially associated with biochemical markers of bone turnover and stiffness in women and men: results from the SHIP cohorts. Osteoporosis International, 2015, 27, 719-727.	2.7	14
156	Impact of Long-Term Exposure to the Tyrosine Kinase Inhibitor Imatinib on the Skeleton of Growing Rats. PLoS ONE, 2015, 10, e0131192.	1.5	39
157	Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells. Molecular Cancer, 2014, 13, .	19.9	20
158	Are there still east-to-west differences in the incidence of hip fractures in Germany?. Archives of Osteoporosis, 2014, 9, .	1.3	7
159	High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients. BMC Cancer, 2014, 14, .	2.1	74
160	Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts. Nature Communications, 2014, 5, .	10.8	194
161	Sulfated Glycosaminoglycans Support Osteoblast Functions and Concurrently Suppress Osteoclasts. Journal of Cellular Biochemistry, 2014, 115, 1101-1111.	1.8	62
162	Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus. Clinical Endocrinology, 2014, 80, 649-655.	1.5	51

#	Article	IF	Citations
163	Effects of Parathyroid Hormone on Bone Mass, Bone Strength, and Bone Regeneration in Male Rats With Type 2 Diabetes Mellitus. Endocrinology, 2014, 155, 1197-1206.	1.8	68
164	Glycosaminoglycans and their sulfate derivatives differentially regulate the viability and gene expression of osteocyte-like cell lines. Journal of Bioactive and Compatible Polymers, 2014, 29, 474-485.	1.1	12
165	Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin. Journal of Bone Oncology, 2014, 3, 18-24.	1.2	10
166	Osteoprotegerin: A new biomarker for impaired bone metabolism in complex regional pain syndrome?. Pain, 2014, 155, 889-895.	3.0	61
167	Oncologic Resection Achieving R0 Margins Improves Disease-Free Survival in Parathyroid Cancer. Annals of Surgical Oncology, 2014, 21, 1891-1897.	1.7	50
168	Severe Abdominal Aortic Calcification in Older Men Is Negatively Associated With DKK1 Serum Levels: The STRAMBO Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 617-624.	3.1	31
169	Outcome of glucose homeostasis in patients with glucocorticoid-induced osteoporosis undergoing treatment with bone active-drugs. Bone, 2014, 67, 175-180.	2.3	23
170	Ebf factors and MyoD cooperate to regulate muscle relaxation via Atp2a1. Nature Communications, 2014, 5, .	10.8	58
171	Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1671-1680.	1.8	31
172	Dickkopf-1 is regulated by the mevalonate pathway in breast cancer. Breast Cancer Research, 2014, 16, .	3.4	35
173	Cathepsin S controls adipocytic and osteoblastic differentiation, bone turnover, and bone microarchitecture. Bone, 2014, 64, 281-287.	2.3	38
174	Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study. Bone, 2014, 58, 48-54.	2.3	151
175	Dickkopf-1 as a mediator and novel target in malignant bone disease. Cancer Letters, 2014, 346, 172-177.	6.5	38
176	Endocrine aspects of bone metastases. Lancet Diabetes and Endocrinology,the, 2014, 2, 500-512.	12.4	114
177	Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cells. Journal of Bone Oncology, 2014, 3, 10-17.	1.2	20
178	Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes and Endocrinology,the, 2014, 2, 830-842.	12.4	124
179	Myelodysplasia is in the niche: novel concepts and emerging therapies. Leukemia, 2014, 29, 259-268.	3.7	76
180	Diagnostik und Therapie der Osteoporose bei Diabetes mellitus. Osteologie, 2014, 23, 100-106.	0.1	0

#	Article	IF	Citations
181	Knochenmetastasen. Osteologie, 2014, 23, 239-244.	0.1	0
182	Rationale, baseline characteristics and methodology of the non-interventional VIVA study in postmenopausal osteoporosis. Osteologie, 2014, 23, 49-55.	0.1	0
183	An exotic cause of exudative enteropathy. American Journal of Case Reports, 2014, 15, 226-229.	0.3	2
184	Monocytic expression of osteoclast-associated receptor (OSCAR) is induced in atherosclerotic mice and regulated by oxidized low-density lipoprotein in vitro. Biochemical and Biophysical Research Communications, 2013, 437, 314-318.	1.5	13
185	Monitoring of the first stages of bone healing with microdialysis. Monthly Notices of the Royal Astronomical Society: Letters, 2013, 84, 76-81.	3.2	11
186	Pheochromocytoma and Gastrointestinal Stromal Tumors in Patients With Neurofibromatosis Type I. American Journal of Medicine, 2013, 126, 174-180.	1.4	39
187	The promotion of osteoclastogenesis by sulfated hyaluronan through interference with osteoprotegerin and receptor activator of NF-κB ligand/osteoprotegerin complex formation. Biomaterials, 2013, 34, 7653-7661.	9.5	35
188	Osteonecrosis of the Jaw After Osteoporosis Therapy With Denosumab Following Long-term Bisphosphonate Therapy. Mayo Clinic Proceedings, 2013, 88, 418-419.	1.9	36
189	Early detection of bone metabolism changes under different antiepileptic drugs (ED-BoM-AED) – A prospective multicenter study. Epilepsy Research, 2013, 106, 417-422.	1.3	19
190	Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. Journal of Bone and Mineral Research, 2013, 28, 627-638.	3.2	115
191	Regulation of VEGF by mevalonate pathway inhibition in breast cancer. Journal of Bone Oncology, 2013, 2, 110-115.	1.2	11
192	Effects of the Selective Glucocorticoid Receptor Modulator Compound A on Bone Metabolism and Inflammation in Male Mice With Collagen-Induced Arthritis. Endocrinology, 2013, 154, 3719-3728.	1.8	44
193	Die Diagnose des Phäochromozytoms und Paraganglioms. Deutsche Medizinische Wochenschrift, 2013, 138, 76-81.	0.1	13
194	Skeletal and Soft Tissue Involvement in Mazabraud Syndrome. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1381-E1382.	3.1	5
195	NADPH oxidase 4 limits bone mass by promoting osteoclastogenesis. Journal of Clinical Investigation, 2013, 123, 4731-4738.	6.6	163
196	Correlates of bone microarchitectural parameters and serum sclerostin levels in men: The STRAMBO study. Journal of Bone and Mineral Research, 2013, 28, 1760-1770.	3.2	48
197	Micro-osmotic pumps for continuous release of the tyrosine kinase inhibitor bosutinib in juvenile rats and its impact on bone growth. Medical Science Monitor Basic Research, 2013, 19, 274-278.	0.6	12
198	The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. Osteoporosis International, 2013, 25, 339-347.	2.7	27

#	Article	IF	Citations
199	Impact Of The Tyrosine Kinase Inhibitors Imatinib, Dasatinib, and Bosutinib In Young Rats On The Vertebral Body. Blood, 2013, 122, 1472-1472.	3.6	4
200	Pulmonary Metastases due to a Giant-Cell Tumor of Bone. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3408-3409.	3.1	3
201	Combined Use of 68Ga-DOTATATE and 18F-FDG PET/CT to Localize a Bronchial Carcinoid Associated with Ectopic ACTH Syndrome. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2207-2208.	3.1	13
202	Endocrine and Clinical Correlates of Myostatin Serum Concentration in Men—the STRAMBO Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3700-3708.	3.1	53
203	Pheochromocytoma – update on disease management. Therapeutic Advances in Endocrinology and Metabolism, 2012, 3, 11-26.	4.1	79
204	Osteometabolic and Osteogenetic Pattern of Turkish Immigrants in Germany. Experimental and Clinical Endocrinology and Diabetes, 2012, 120, 517-523.	0.9	10
205	Selective glucocorticoid receptor modulation maintains bone mineral density in mice. Journal of Bone and Mineral Research, 2012, 27, 2242-2250.	3.2	82
206	A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporosis International, 2012, 23, 2257-2276.	2.7	317
207	Lokale und systemische Knocheneffekte bei rheumatoider Arthritis. Zeitschrift Fur Rheumatologie, 2012, 71, 869-874.	0.7	4
208	Osteoprotegerin (OPG) and TNF-related apoptosis-inducing ligand (TRAIL) levels in malignant and benign pericardial effusions. Clinical Biochemistry, 2012, 45, 237-242.	1.2	13
209	Impact of lenalidomide on the functional properties of human mesenchymal stromal cells. Experimental Hematology, 2012, 40, 867-876.	0.6	29
210	Differential effects of mixed lymphocyte reaction supernatant on human mesenchymal stromal cells. Experimental Hematology, 2012, 40, 934-944.	0.6	19
211	Quantitative proteomics reveals novel functions of osteoclast-associated receptor in STAT signaling and cell adhesion in human endothelial cells. Journal of Molecular and Cellular Cardiology, 2012, 53, 829-837.	2.7	16
212	Serum Level of the Phosphaturic Factor FGF23 Is Associated with Abdominal Aortic Calcification in Men: The STRAMBO Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E575-E583.	3.1	77
213	Krüppel-like factors KLF2 and 6 and Ki-67 are direct targets of zoledronic acid in MCF-7 cells. Bone, 2012, 50, 723-732.	2.3	22
214	Regulation of bone mass and osteoclast function depend on the F-actin modulator SWAP-70. Journal of Bone and Mineral Research, 2012, 27, 2085-2096.	3.2	45
215	The effect of the degree of sulfation of glycosaminoglycans on osteoclast function and signaling pathways. Biomaterials, 2012, 33, 8418-8429.	9.5	79
216	An appendix to the 2012 IOF–ECTS guidelines for the management of glucocorticoid-induced osteoporosis. Archives of Osteoporosis, 2012, 7, 25-30.	1.3	36

#	Article	IF	Citations
217	Keine Schmerzen, großer Schaden. MMW Fortschritte Der Medizin, 2012, 154, 5-5.	0.0	0
218	Denosumab for Post-Transplantation Hypercalcemia in Osteopetrosis. New England Journal of Medicine, 2012, 367, 1766-1767.	26.4	45
219	Calcification inhibitors in vascular calciphylaxis associated with normal renal function. Thrombosis and Haemostasis, 2012, 108, 1241-1243.	2.3	7
220	WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. Journal of Bone and Mineral Research, 2012, 27, 575-585.	3.2	111
221	Bone, sweet bone—osteoporotic fractures in diabetes mellitus. Nature Reviews Endocrinology, 2012, 8, 297-305.	20.1	356
222	The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. Nature Immunology, 2012, 13, 465-473.	14.1	423
223	Skeletal and extraskeletal actions of denosumab. Endocrine, 2012, 42, 52-62.	1.8	40
224	The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leukemia Research, 2012, 36, 525-536.	0.7	81
225	Novel therapies in benign and malignant bone diseases. , 2012, 134, 338-344.		24
226	Skeletal Effects of the Tyrosine Kinase Inhibitors Imatinib, Dasatinib, and Bosutinib in Young Rats. Blood, 2012, 120, 4429-4429.	3.6	1
227	Measurements of Plasma Methoxytyramine, Normetanephrine, and Metanephrine as Discriminators of Different Hereditary Forms of Pheochromocytoma. Clinical Chemistry, 2011, 57, 411-420.	0.6	293
228	Optimizing management of myelodysplastic syndromes post-allogeneic transplantation. Expert Review of Hematology, 2011, 4, 669-680.	1.5	2
229	miR-125b Regulates Calcification of Vascular Smooth Muscle Cells. American Journal of Pathology, 2011, 179, 1594-1600.	2.8	178
230	The anti-progestin RU-486 inhibits viability of MCF-7 breast cancer cells by suppressing WNT1. Cancer Letters, 2011, 312, 101-108.	6.5	13
231	Crystallizing nanoparticles derived from vascular smooth muscle cells contain the calcification inhibitor osteoprotegerin. Biochemical and Biophysical Research Communications, 2011, 407, 103-107.	1.5	27
232	Osteoporosis: now and the future. Lancet, The, 2011, 377, 1276-1287.	46.9	2,544
233	Metabolic bone diseases in patients after allogeneic hematopoietic stem cell transplantation: Report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Transplant International, 2011, 24, 867-879.	1.7	37
234	The Osteoclast-Associated Receptor (OSCAR) Is a Novel Receptor Regulated by Oxidized Low-Density Lipoprotein in Human Endothelial Cells. Endocrinology, 2011, 152, 4915-4926.	1.8	39

#	Article	IF	Citations
235	Probleme und Kontroversen in der Behandlung von Sprunggelenkfrakturen. Der Unfallchirurg, 2011, 114, 847-860.	0.6	64
236	Nuclear factor of activated T cells mediates oxidised LDL-induced calcification of vascular smooth muscle cells. Diabetologia, 2011, 54, 2690-2701.	4.9	53
237	Is there still a place for adrenal venous sampling in the diagnostic localization of pheochromocytoma?. Endocrine, 2011, 40, 75-79.	1.8	7
238	Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. Journal of Cellular Biochemistry, 2011, 112, 1593-1600.	1.8	51
239	Dissociation of Osteogenic and Immunological Effects by the Selective Glucocorticoid Receptor Agonist, Compound A, in Human Bone Marrow Stromal Cells. Endocrinology, 2011, 152, 103-112.	1.8	50
240	Seizures Associated with Zoledronic Acid for Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1955-1959.	3.1	27
241	An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. FASEB Journal, 2011, 25, 1323-1332.	2.3	71
242	Cortical Bone Status Is Associated with Serum Osteoprotegerin Concentration in Men: The STRAMBO Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2216-2226.	3.1	24
243	Disruption of a Nuclear NFATc2 Protein Stabilization Loop Confers Breast and Pancreatic Cancer Growth Suppression by Zoledronic Acid. Journal of Biological Chemistry, 2011, 286, 28761-28771.	1.3	28
244	Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function. American Journal of Physiology - Endocrinology and Metabolism, 2011, 301, E1220-E1228.	2.5	138
245	The Role of Osteoclast-Associated Receptor in Osteoimmunology. Journal of Immunology, 2011, 186, 13-18.	0.8	78
246	Regenerative potential of glycosaminoglycans for skin and bone. Journal of Molecular Medicine, 2011, 90, 625-635.	2.8	185
247	Diskussion über die optimale Dosis von Vitamin D. Osteologie, 2011, 20, 149-151.	0.1	1
248	A novel resorption assay for osteoclast functionality based on an osteoblast-derived native extracellular matrix. Journal of Cellular Biochemistry, 2010, 109, 1025-1032.	1.8	44
249	Sexualsteroide in der Homöostase des Knochens. Osteologie, 2010, 19, 105-110.	0.1	2
250	Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Letters, 2010, 287, 109-116.	6.5	60
251	Die Osteoporose des Mannes. Osteologie, 2010, 19, 131-135.	0.1	1
252	Bedeutung des RANK/RANKL/OPGSignalwegs für den Knochenstoffwechsel. Osteologie, 2010, 19, 354-357.	0.1	0

#	Article	IF	Citations
253	Long-Term Cyclic Strain Downregulates Endothelial Nox4. Antioxidants and Redox Signaling, 2009, 11, 2385-2397.	4.1	39
254	Minireview: Live and Let Die: Molecular Effects of Glucocorticoids on Bone Cells. Molecular Endocrinology, 2009, 23, 1525-1531.	2.5	85
255	Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. Journal of Cellular Biochemistry, 2009, 108, 106-116.	1.8	36
256	Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis and Rheumatism, 2009, 60, 1427-1437.	6.1	131
257	Medial arterial calcification in diabetes and its relationship to neuropathy. Diabetologia, 2009, 52, 2478-2488.	4.9	105
258	Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial. Journal of Bone and Mineral Research, 2009, 24, 153-161.	3.2	543
259	Inhibition of Lamin A/C Attenuates Osteoblast Differentiation and Enhances RANKL-Dependent Osteoclastogenesis. Journal of Bone and Mineral Research, 2009, 24, 78-86.	3.2	64
260	Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats. Bone, 2009, 45, 677-681.	2.3	41
261	Inhibition of Receptor Activator of NF-κB Ligand by Denosumab Attenuates Vascular Calcium Deposition in Mice. American Journal of Pathology, 2009, 175, 473-478.	2.8	153
262	Multimodal Therapy for Vertebral Involvement of Systemic Mastocytosis. Spine, 2009, 34, E626-E628.	1.8	9
263	Klinik und Diagnostik der Osteoporose und Osteomalazie. Der Internist, 2008, 49, 1170-1177.	0.4	4
264	Interleukin-4 and Interleukin-13 Stimulate the Osteoclast Inhibitor Osteoprotegerin by Human Endothelial Cells Through the STAT6 Pathway. Journal of Bone and Mineral Research, 2008, 23, 750-758.	3.2	79
265	Fatal attraction: why breast cancer cells home to bone. Breast Cancer Research, 2008, 10, .	3.4	35
266	17β-Estradiol inhibits osteoprotegerin production by the estrogen receptor-α-positive human breast cancer cell line MCF-7. Biochemical and Biophysical Research Communications, 2008, 368, 736-741.	1.5	25
267	Exploring the biology of vascular calcification in chronic kidney disease: What's circulating?. Kidney International, 2008, 73, 384-390.	4.2	121
268	The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not Matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrology Dialysis Transplantation, 2008, 23, 3263-3271.	0.7	160
269	Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells. Molecular and Cellular Endocrinology, 2007, 264, 74-81.	2.0	48
270	Osteoprotegerin expression in dendritic cells increases with maturation and is NF-κB-dependent. Journal of Cellular Biochemistry, 2007, 100, 1430-1439.	1.8	41

#	Article	IF	Citations
271	Osteoporosis in Patients With Diabetes Mellitus. Journal of Bone and Mineral Research, 2007, 22, 1317-1328.	3.2	448
272	Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death. Diabetologia, 2007, 50, 1243-1247.	4.9	50
273	Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine, 2007, 31, 105-113.	1.8	29
274	Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis, 2006, 184, 446-447.	1.9	65
275	Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG). Annales D'Endocrinologie, 2006, 67, 139-141.	0.2	31
276	Interleukin-4 differentially regulates osteoprotegerin expression and induces calcification in vascular smooth muscle cells. Thrombosis and Haemostasis, 2006, 95, 708-714.	2.3	32
277	Functional Thyrotropin Receptor Attenuates Malignant Phenotype of Follicular Thyroid Cancer Cells. Endocrine, 2006, 30, 129-138.	1.4	18
278	Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporosis International, 2006, 17, 693-703.	2.7	75
279	Paneling human thyroid cancer cell lines for candidate proteins for targeted anti-angiogenic therapy. Journal of Cellular Biochemistry, 2006, 98, 954-965.	1.8	12
280	Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. Rheumatology, 2006, 45, 1218-1222.	1.4	57
281	Vascular calcification and osteoporosis—from clinical observation towards molecular understanding. Osteoporosis International, 2006, 18, 251-259.	2.7	222
282	Osteoprotegerin (OPG) protects pancreatic beta cells from Interleukin-1 induced cell death. Experimental and Clinical Endocrinology and Diabetes, 2006, 114, .	0.9	0
283	Gorham-Stout Disease-Stabilization During Bisphosphonate Treatment. Journal of Bone and Mineral Research, 2005, 20, 350-353.	3.2	100
284	Isopropanolic Extract of Black Cohosh Stimulates Osteoprotegerin Production by Human Osteoblasts. Journal of Bone and Mineral Research, 2005, 20, 2036-2043.	3.2	33
285	Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. Journal of Cellular Biochemistry, 2005, 96, 1244-1253.	1.8	68
286	Expression of bone-regulating factors osteoprotegerin (OPG) and receptor activator of NF-κB ligand (RANKL) in heterotopic vascular ossification. Thrombosis and Haemostasis, 2005, 94, 1335-1337.	2.3	12
287	Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochemical and Biophysical Research Communications, 2005, 338, 687-693.	1.5	68
288	TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy. Biochemical and Biophysical Research Communications, 2005, 338, 1745-1750.	1.5	26

#	Article	IF	Citations
289	Osteoprotegerin Gene Polymorphisms in Men with Coronary Artery Disease. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3764-3768.	3.1	91
290	Thyrotropin (TSH)-Induced Production of Vascular Endothelial Growth Factor in Thyroid Cancer Cellsin Vitro: Evaluation of TSH Signal Transduction and of Angiogenesis-Stimulating Growth Factors. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 6139-6145.	3.1	71
291	Localization of Osteoprotegerin, Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand, and Receptor Activator of Nuclear Factor-κB Ligand in Mönckeberg's Sclerosis and Atherosclerosis. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4104-4112.	3.1	190
292	Expression of receptor activator of NF-?B ligand (RANKL) mRNA in human multiple myeloma cells. Journal of Cancer Research and Clinical Oncology, 2004, 130, .	1.8	29
293	Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid. Acta Neuropathologica, 2004, 107, 575-577.	5.8	18
294	Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clinical Endocrinology, 2004, 60, 214-219.	1.5	51
295	Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases. JAMA - Journal of the American Medical Association, 2004, 292, 490.	14.4	887
296	Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood, 2004, 103, 3480-3489.	3.6	97
297	Novel Aspects on RANK Ligand and Osteoprotegerin in Osteoporosis and Vascular Disease. Calcified Tissue International, 2003, 74, 103-106.	1.7	103
298	Familial severe congenital neutropenia associated with infantile osteoporosis: A new entity. American Journal of Hematology, 2003, 72, 34-37.	5.2	12
299	Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. Alimentary Pharmacology and Therapeutics, 2003, 17, 807-816.	2.7	62
300	Low Serum Levels of Soluble RANK Ligand Are Associated With the Presence of Coronary Artery Disease in Men. Circulation, 2003, 107, .	13.1	51
301	Increased Osteoprotegerin Serum Levels in Men with Coronary Artery Disease. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1024-1028.	3.1	305
302	Raloxifene Concurrently Stimulates Osteoprotegerin and Inhibits Interleukin-6 Production by Human Trabecular Osteoblasts. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4206-4213.	3.1	97
303	Skeletal Effects of Cyclosporin A Are Gender Related in Rats. Endocrinology, 2003, 144, 40-49.	1.8	24
304	Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. European Journal of Gastroenterology and Hepatology, 2003, 15, 1165-1170.	1.1	46
305	Osteoprotegerin Deficiency and Juvenile Paget's Disease. New England Journal of Medicine, 2002, 347, 1622-1623.	26.4	11
306	In Vitro and in Vivo Angiogenesis in PC12 Pheochromocytoma Cells is Mediated by Vascular Endothelial Growth Factor. Experimental and Clinical Endocrinology and Diabetes, 2002, 110, 386-392.	0.9	39

#	Article	IF	Citations
307	Osteoprotegerin Gene Polymorphism and the Risk of Osteoporosis and Vascular Disease. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4078-4079.	3.1	41
308	Dehydroepiandrosterone Supplementation in Elderly Men: The Role of Estrogens Versus Androgens on the Male Skeleton. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4009-4009.	3.1	1
309	RANK Ligand and Osteoprotegerin. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 549-553.	4.3	369
310	Bisphosphonates Pamidronate and Zoledronic Acid Stimulate Osteoprotegerin Production by Primary Human Osteoblasts. Biochemical and Biophysical Research Communications, 2002, 291, 680-686.	1.5	277
311	VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery, 2002, 132, 1056-1063.	1.6	57
312	Cytokine inhibition: a new therapeutic avenue for skeletal diseases. Drug Discovery Today, 2002, 7, 289.	5.0	0
313	Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. Journal of Cellular Biochemistry, 2002, 84, 725-735.	1.8	95
314	Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. Journal of Cellular Biochemistry, 2002, 86, 642-650.	1.8	40
315	Dehydroepiandrosterone Supplementation in Elderly Men: The Role of Estrogens Versus Androgens on the Male Skeleton. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4009-4009.	3.1	2
316	Effects of Immunosuppressants on Receptor Activator of NF-κB Ligand and Osteoprotegerin Production by Human Osteoblastic and Coronary Artery Smooth Muscle Cells. Biochemical and Biophysical Research Communications, 2001, 280, 334-339.	1.5	203
317	Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology. Journal of Molecular Medicine, 2001, 79, 243-253.	2.8	537
318	Receptor activator of nuclear factor-κB ligand and osteoprotegerin. Cancer, 2001, 92, 460-470.	2.7	171
319	The role of osteoprotegerin and receptor activator of nuclear factor ?B ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis and Rheumatism, 2001, 44, 253-259.	6.1	90
320	Bone and Mineral Metabolism in Human Immunodeficiency Virus Infection. Journal of Bone and Mineral Research, 2001, 16, 2-9.	3.2	38
321	Identical twins with hypercalcaemia due to Lowe's syndrome. Rheumatology, 2001, 40, 107-108.	1.4	2
322	Leptin Reduces Ovariectomy-Induced Bone Loss in Rats. Endocrinology, 2001, 142, 3546-3553.	1.8	277
323	Osteoprotegerin Serum Levels in Men: Correlation with Age, Estrogen, and Testosterone Status1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3162-3165.	3.1	193
324	Osteoprotegerin-Ligand und Osteoprotegerin - Neue Konzepte in der Pathogenese und Therapie metabolischer Knochenerkrankungen -. Deutsche Medizinische Wochenschrift, 2001, 126, 145-150.	0.1	7

#	Article	IF	Citations
325	The Expression of Osteoprotegerin and RANK Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells Is Developmentally Regulated**This work was supported by Grant AG-04875 from the National Institute on Aging.. Endocrinology, 2000, 141, 4768-4776.	1.8	271
326	The Role of Receptor Activator of Nuclear Factor-κB Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases 1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2355-2363.	3.1	150
327	Transforming-growth factor-b als protektiver Faktor der autoimmunen Pankreatitis. Zeitschrift Fur Gastroenterologie, 2000, 38, 653-654.	0.1	0
328	The Expression of Osteoprotegerin and RANK Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells Is Developmentally Regulated. Endocrinology, 2000, 141, 4768-4776.	1.8	73
329	The Role of Receptor Activator of Nuclear Factor- B Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2355-2363.	3.1	119
330	Effects of Androgens on the Insulin-Like Growth Factor System in an Androgen-Responsive Human Osteoblastic Cell Line. Endocrinology, 1999, 140, 5579-5586.	1.8	84
331	Estrogen Stimulates Gene Expression and Protein Production of Osteoprotegerin in Human Osteoblastic Cells*. Endocrinology, 1999, 140, 4367-4370.	1.8	610
332	Gorham–Stout disease (phantom bone) of the shoulder girdle. Rheumatology, 1999, 38, 904-905.	1.4	14
333	Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis1. Endocrinology, 1999, 140, 4382-4389.	1.8	723
334	The Anti-Androgen Hydroxyflutamide and Androgens Inhibit Interleukin-6 Production by an Androgen-Responsive Human Osteoblastic Cell Line. Journal of Bone and Mineral Research, 1999, 14, 1330-1337.	3.2	65
335	Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone, 1999, 25, 255-259.	2.3	595
336	Raloxifen. Deutsche Medizinische Wochenschrift, 1999, 124, 19-20.	0.1	0
337	Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis. Endocrinology, 1999, 140, 4382-4389.	1.8	208
338	Effects of Androgens on the Insulin-Like Growth Factor System in an Androgen-Responsive Human Osteoblastic Cell Line. Endocrinology, 1999, 140, 5579-5586.	1.8	29
339	Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line. Journal of Cellular Biochemistry, 1998, 71, 96-108.	1.8	53
340	Osteoprotegerin Production by Human Osteoblast Lineage Cells Is Stimulated by Vitamin D, Bone Morphogenetic Protein-2, and Cytokines. Biochemical and Biophysical Research Communications, 1998, 250, 776-781.	1.5	287
341	Bone morphogenetic protein-6 production in human osteoblastic cell lines. Selective regulation by estrogen.. Journal of Clinical Investigation, 1998, 101, 413-422.	6.6	87
342	Soluble Interleukin-1 Receptor Antagonist Serum Levels in Smokers and Nonsmokers with Graves' Ophthalmopathy Undergoing Orbital Radiotherapy1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2244-2247.	3.1	56

#	Article	IF	Citations
343	Aktueller Stand zur Therapie mit Bisphosphonaten. Deutsche Medizinische Wochenschrift, 1997, 122, 835-841.	0.1	1
344	Graves Disease Associated With Autoimmune Thrombocytopenic Purpura. Archives of Internal Medicine, 1997, 157, 1033.	8.1	26
345	Endokrine Störungen und hormonelle Therapie bei HIV-Infektion. Deutsche Medizinische Wochenschrift, 1997, 122, 621-626.	0.1	0
346	Endocrine and Metabolic Complications in Alagille's Syndrome. Medizinische Klinik, 1997, 92, 528-533.	0.1	2
347	Mediastinal parathyroid tumor: Giant adenoma or carcinoma?. Endocrine Pathology, 1997, 8, 161-166.	2.2	5
348	Development and characterization of a conditionally immortalized human osteoblastic cell line stably transfected with the human androgen receptor gene. , 1997, 66, 542-551.		24
349	Soluble Interleukin-1 Receptor Antagonist Serum Levels in Smokers and Nonsmokers with Graves' Ophthalmopathy Undergoing Orbital Radiotherapy. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2244-2247.	3.1	55
350	Endocrine Implications of Human Immunodeficiency Virus Infection. Medicine (United States), 1996, 75, 262-278.	1.0	62
351	Pathogenese, Diagnose und Therapie der Posttransplantations-Osteoporose. Deutsche Medizinische Wochenschrift, 1996, 121, 953-957.	0.1	4
352	Greetings from below the aortic arch! The paradigm of cardiac paraganglioma.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 891-895.	3.1	5
353	Infektiöse Thyreoiditis als Erstmanifestation einer embolisierenden Aortenklappen-Endokarditis*. Deutsche Medizinische Wochenschrift, 1996, 121, 369-374.	0.1	2
354	Molekulare Pathogenese der Adipositas: Physiologische und pathophysiologische Rolle von Leptin. Deutsche Medizinische Wochenschrift, 1996, 121, 1134-1138.	0.1	1
355	Rheumatoide Arthritis, Neutropenie und Splenomegalie: Felty-Syndrom. Deutsche Medizinische Wochenschrift, 1995, 120, 1689-1694.	0.1	10
356	Lakunärer Hirninfarkt bei einer jungen Frau. Deutsche Medizinische Wochenschrift, 1995, 120, 1777-1782.	0.1	1
357	Title is missing!. , 0, .		3
358	Title is missing!. , 0, .		1
359	Glucocorticoid-induced osteoporosis: novel concepts and clinical implications. Lancet Diabetes and Endocrinology,the, 0, 13, 964-979.	12.4	52
360	Rac1 inhibition promotes antitumor activity of statins in bone-seeking breast cancer cells. Biochemical and Biophysical Research Communications, 0, 792, 152967.	1.5	0

#	Article	IF	Citations
361	Iron overload induced by ferric derisomaltose and ferric carboxymaltose both increase FGF-23 levels and lead to osteomalacia and bone loss in normal mice. BioMetals, 0, 39, 953-971.	2.4	0
362	Thra knockout protects male mice from hyperthyroidism-driven cortical bone loss by mitigating bone resorption. JBMR Plus, 0, 10, .	1.5	0
363	Deconstructing senescence phenotypes in cells of the bone and bone marrow. Journal of Clinical Investigation, 0, 136, .	6.6	0
364	Increased fracture risk associated with iron-deficiency anemia: a population-based propensity score matched cohort study. Osteoporosis International, 0, , .	2.7	0